CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 54 enrolled
Drug / intervention
Liposomal bupivacaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03149887
NCT03149887Phase 4Completed
CompareCT.gov

Use of Liposomal Bupivacaine for Postoperative Pain Management After Arthroscopic Rotator Cuff Repair

Steven Orebaugh·interventional·Posted May 11, 2017·Updated Jan 23, 2020

In Brief

A Phase 4 clinical trial evaluating Liposomal bupivacaine and Placebo for Rotator Cuff Tear. Completed, enrolled 54 participants across 1 site.

Detailed Summary

Liposomal bupivacaine, a long-acting form of bupivacaine, has been found to be effective for postoperative pain control after total knee, total hip and total shoulder arthroplasty. We are conducting a randomized, controlled trial to evaluate pain control after arthroscopic rotator cuff repair in ambulatory patients, comparing standard care in the control group, with standard care plus the addition of injection of liposomal bupivacaine in the experimental group.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRotator Cuff Tear
CountriesUnited States
CollaboratorsPacira Pharmaceuticals, Inc

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedMay 11, 2017
Enrollment StartDec 5, 2017
Primary CompletionFeb 26, 2019
Study CompletionMar 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.1 years ago

Interventions

Liposomal bupivacainedrug

Liposomal bupivacaine solution (Exparel) for injection

Placebodrug

Inert solution created to appear as liposomal bupivacaine (Exparel) for injection